

IFN

In re Application of: **Eszter Birck-Wilson et al.**Serial No.: **10/659,856**Group No.: **1644**Filed: **09/11/2003**

Examiner:

For: **Isolation of Immune Globulin Molecules That Lack Inter-Heavy Chain Disulfide Bonds**Attorney Docket Number: **GTC-56**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING APPLICATION OR BEFORE MAILING OF A
FIRST OFFICE ACTION ON THE MERITS (37 CFR 1.97(b))**

1. Authority

Pursuant to 37 CFR §§ 1.56 and 1.97-1.99, the Applicant cites to the Examiner documents containing information which, in good-faith judgment of the Applicant, may be relevant to the subject matter claimed in the above-identified application. The Applicant also encloses copies of the English-language cited documents.

In submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, or the extent of any search performed, or that more relevant information does not exist.


In submitting this Information Disclosure Statement, the Applicant makes no representation that any document cited in this Information Disclosure Statement is, or is considered to be prior art as defined by 35 USC §§ 102 and 103.

2. Time of Transmittal of Accompanying Information Disclosure Statement

The Information Disclosure Statement transmitted herewith is being filed *after* three months of the filing date of this national application but *before* the mailing date of the first

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that on September 24, 2004 this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Kristin Kaberry

Office action on the merits.

A copy of the PCT International Search Report from a counterpart application is enclosed. Legible copies of all items listed in Form PTO-1449 accompany this information statement. Cumulative patents or publications identified in the attached PCT Search Report are not enclosed.

I hereby certify that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. 37 CFR 1.97 (e) (1).

It is Applicant's understanding that no fee is due; however, if the Applicant is incorrect, please charge any necessary fees for the above-captioned application to Deposit Account No. 502092.

The Applicant respectfully requests that:

- a. The Examiner consider the cited information in reaching a determination concerning the patentability of the pending claims; and
- b. The enclosed Form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

The person making this statement is the attorney who signs below on the basis of the information in the attorney's file.

Respectfully submitted,

Dated: _____

9/23/04

By: _____



Byron V. Olsen, Reg. No. 42,960
Attorney for Applicants
Taurus hSA LLC
175 Crossing Blvd., Suite 410
Framingham, MA 01702
Tel. #(508) 370-5150 Fax #(508) 370-3797

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/659,856

Filing Date 09/11/2003

First Named Inventor Eszter Birck-Wilson

Art Unit 1644

Examiner Name

Attorney Docket Number GTC-56

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kretzschmar et al., "High-level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies", J. of Immunol. Methods, pgs. 93-101 (1996)	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.